GIA
HZNP

Gladstone Institutional Advisory’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gladstone Institutional Advisory’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,303
Closed -$356K – 772
2021
Q4 		$356K Sell
3,303
-962
-23% -$105K 0.03% 441
2021
Q3 		$467K Buy
+4,265
New +$443K 0.05% 347

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gladstone Institutional Advisory's HZNP Position: Q1 2022 in Review

Gladstone Institutional Advisory sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 3,303 shares — an estimated $356K sold.

Gladstone Institutional Advisory first reported a position in HZNP in Q3 2021 and held it in 2 quarters. The position peaked at $467K in Q3 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

  • Gladstone Institutional Advisory reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 3,303 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $356K.
  • Gladstone Institutional Advisory first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 2 quarters.
  • Gladstone Institutional Advisory's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $467K in Q3 2021.
  • 620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2022, filed 4 May 2022.